शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
CIPLANSECipla Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 23 Jan, 2026 · 14:09 IST

Cipla re-appoints P R Ramesh as Independent Director for 5 years

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.8%Reaction day
₹1374.00
prior close
₹1323.70
announcement price
In-mkt
timing
Nifty 100market · index membership as recorded later (tracked since Jun 2026)-1.1%-2.6% vs market
Pharmaceuticals peers, median of 155sector-1.5%-2.2% vs sector

On the reaction day the stock moved 2.6 pts less than Nifty 100 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.3
10m
+0.2
15m
-0.3
30m
-0.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.8-1.1-2.6-1.5-2.2
Next day
-4.4-0.6-3.8-2.0-2.4
2d
-2.9+0.3-3.2-0.9-1.9
3d
-4.0+0.6-4.6-1.3-2.7
4d
-3.6+0.2-3.7-1.1-2.5
5d
-4.3-0.8-3.5-1.3-3.0
1w
-3.3+2.0-5.3+1.5-4.8
15d
-1.4+1.8-3.1+0.2-1.6
1m
-3.4+1.9-5.3+0.3-3.7
2m
-11.2-10.7-0.5-9.9-1.3
3m
-4.9-3.0-1.9+2.8-7.6
UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cipla's Board has approved the re-appointment of Mr P R Ramesh (DIN: 01915274) as Independent Director for a second term of five consecutive years, from 1 July 2026 to 30 June 2031, subject to shareholder approval. He has been on Cipla's Board since 1 July 2021 and chairs the Audit Committee. He is a retired Director of Deloitte and also serves on boards of Air India, L&T, Nestle India, Crompton Greaves Consumer Electricals, and ITC Hotels.

Likely market impact

Routine governance continuity. No change in control or strategy expected; pending shareholder approval.